Fennec Pharmaceuticals Inc (NASDAQ:FENC) Given Consensus Rating of “Buy” by Analysts

Fennec Pharmaceuticals Inc (NASDAQ:FENC) has been given a consensus rating of “Buy” by the six research firms that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have given a buy recommendation to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $16.50.

Several research firms recently issued reports on FENC. HC Wainwright set a $55.00 price target on Acer Therapeutics and gave the company a “buy” rating in a research report on Tuesday, May 28th. Wedbush set a $38.00 price target on Obseva and gave the company a “buy” rating in a research report on Friday, May 10th. Finally, Zacks Investment Research raised General Moly from a “sell” rating to a “hold” rating in a research report on Thursday, July 11th.

Shares of FENC traded down $0.02 during trading on Friday, reaching $3.90. The company’s stock had a trading volume of 2,090 shares, compared to its average volume of 157,981. The business’s fifty day moving average price is $3.90. Fennec Pharmaceuticals has a twelve month low of $3.26 and a twelve month high of $10.61. The company has a market cap of $75.82 million, a P/E ratio of -7.66 and a beta of -0.15.

Fennec Pharmaceuticals (NASDAQ:FENC) last posted its quarterly earnings results on Thursday, May 9th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.14) by $0.01. Equities research analysts predict that Fennec Pharmaceuticals will post -0.59 EPS for the current year.

Several hedge funds have recently bought and sold shares of FENC. Rhumbline Advisers bought a new position in Fennec Pharmaceuticals during the 4th quarter worth $87,000. Weiss Multi Strategy Advisers LLC bought a new position in Fennec Pharmaceuticals during the 4th quarter worth $160,000. Geode Capital Management LLC grew its stake in Fennec Pharmaceuticals by 16.0% during the 4th quarter. Geode Capital Management LLC now owns 39,489 shares of the company’s stock worth $251,000 after buying an additional 5,441 shares during the last quarter. United Services Automobile Association grew its stake in Fennec Pharmaceuticals by 87.4% during the 4th quarter. United Services Automobile Association now owns 154,190 shares of the company’s stock worth $984,000 after buying an additional 71,922 shares during the last quarter. Finally, BlackRock Inc. grew its stake in Fennec Pharmaceuticals by 0.4% during the 4th quarter. BlackRock Inc. now owns 562,216 shares of the company’s stock worth $3,588,000 after buying an additional 2,429 shares during the last quarter. 48.46% of the stock is currently owned by institutional investors and hedge funds.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.

See Also: What is a Buy-Side Analyst?

Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.